^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Papitrol (tirvalimogene teraplasmid)

    i
    Other names: GX-188E, GX-188, pGX27-E6E7, NOV1702
    Company:
    Genexine, National OncoVenture
    Drug class:
    Immunostimulant
    Related drugs:
    7d
    TRINITY: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Yonsei University | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Jan 2027 | Trial primary completion date: Mar 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    4ms
    GENUINE: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, Yonsei University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    over1year
    GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial. (PubMed, EClinicalMedicine)
    This combination therapy might provide a new potential treatment option for patients with recurrent or advanced cervical cancer. National Cancer Center Onco-Innovation Unit, Korea.
    P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)
    over2years
    KEYNOTE-567: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer (clinicaltrials.gov)
    P1/2, N=65, Completed, Genexine, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)
    over2years
    GENUINE: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (clinicaltrials.gov)
    P2, N=56, Recruiting, Yonsei University | N=25 --> 56 | Trial primary completion date: Dec 2025 --> Aug 2025
    Enrollment change • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    3years
    Lunit to Present 16 Abstracts at the 2023 ASCO Annual Meeting (PRNewswire)
    "Lunit...announced the presentation of 16 abstracts featuring its AI-biomarker platform at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois, on June 2-6."
    Clinical data • P2 data
    |
    Lunit SCOPE IO
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    3years
    TRINITY: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting
    Combination therapy • Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 28-8 pharmDx
    |
    Opdivo (nivolumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    4years
    GENUINE: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Yonsei University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    4years
    KEYNOTE-567: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, Genexine, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Dec 2022
    Enrollment closed • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)
    over4years
    GENUINE: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Yonsei University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    over4years
    TRINITY: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy (clinicaltrials.gov)
    P2; N=21; Not yet recruiting; Sponsor:Yonsei University
    Combination therapy • New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 28-8 pharmDx
    |
    Opdivo (nivolumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    almost6years
    The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Genexine, Inc. | N=46 --> 60 | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2020 --> Dec 2021
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid)